For anyone in Ucgol looking to source CJC-1295, the first thing to know is that this compound is distributed via specialist online vendors. The key implication for Ucgol researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the framework for evaluating that quality is universal across all locations. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. What follows is a sourcing and quality evaluation guide built specifically around CJC-1295, covering everything a Ucgol researcher needs before placing a first order.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Ucgol comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Buying CJC-1295: Quality Markers to Look For
Quality CJC-1295 sourcing begins with a straightforward question: does this vendor share complete COA data without being asked? Suppliers that publish proactively are demonstrating research-grade standards. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from bacterial cell wall components can trigger severe inflammatory responses even at minute levels. Red flags in CJC-1295 vendor evaluation: prices far under typical market pricing, unclear production details, no community presence, and COAs that omit endotoxin testing. Price is an poor proxy for CJC-1295 quality — research-grade synthesis and testing has unavoidable expenses that low-priced vendors are not absorbing, so the lowest-priced options almost always involve trade-offs.
Order CJC-1295 — ships to Ucgol
COA-verified · International tracking · Research grade
All use of CJC-1295 in Ucgol or anywhere is research use only — this compound is not approved for human therapeutic use, and all handling should comply with standard research safety practices. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. The main safety concern arising from sourcing in CJC-1295 research is bacterial endotoxin from low-quality material — a verified endotoxin panel in the batch COA is the key safeguard. Protocol documentation — keeping clear records of compound, timing, and method — is a fundamental research principle that makes anomalous results interpretable.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
